News

The first additional project includes ‘an amendment of the existing collaboration and license agreement for the anti-SIRPα immuno-oncology compounds BI 765063 and BI 770371, which are being investigated in phase 1 clinical studies in advanced solid tumours, development will now also be pursued in cardiovascular-renal-metabolic (CRM) diseases’ and ‘a new preclinical programme will be launched to develop immune-cell activating treatments based on OSE’s cis-targeting anti-PD1/cytokine platform via an asset acquisition’, according to the press release.

Under the terms of the expansion to the agreement, OSE will receive an upfront payment of €13.5m and a potential €17.5m in milestone payments.

Clive R Wood, corporate senior vice president and global head of discovery research at Boehringer Ingelheim, commented: “We are very pleased to expand our pipeline of potential first-in-class CRM disease therapies, as well as our pipeline of first-in-class T-cell based anti-cancer therapies. The expansion of our partnership with OSE reflects our joint mission to improving patient outcomes in two of the biggest threats to global health.”

Nicolas Poirier, CEO of OSE Immunotherapeutics, added: “We are excited about adding two highly innovative new development programmes to our fruitful collaboration with Boehringer Ingelheim. We look forward to working with the scientists at Boehringer Ingelheim on the new development programmes that have the potential to bring new breakthrough therapy options to patients with CRM diseases and cancer.”